Current landscape of cystic fibrosis gene therapy

被引:0
|
作者
Plasschaert, Lindsey W. [1 ]
MacDonald, Kelvin D. [2 ,3 ]
Moffit, Jeffrey S. [2 ]
机构
[1] Plasschaert Consulting, Cambridge, MA USA
[2] Carbon Biosci, Waltham, MA 95648 USA
[3] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA
关键词
cystic fibrosis; CFTR; gene therapy; viral vector; airway; transduction; TRANSMEMBRANE CONDUCTANCE REGULATOR; STRUCTURAL LUNG-DISEASE; ADENOASSOCIATED VIRUS; IN-VITRO; AEROSOL DELIVERY; CLEARANCE INDEX; DOUBLE-BLIND; AAV-CFTR; R-DOMAIN; PHASE-I;
D O I
10.3389/fphar.2024.1476331
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cystic fibrosis is a life-threatening disease that is caused by mutations in CFTR, a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three decades of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression in vitro and in vivo through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where CFTR needs to be expressed, the most advanced vectors for CFTR delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Current dilemmas in antimicrobial therapy in cystic fibrosis
    Jain, Kamini
    Smyth, Alan R.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2012, 6 (04) : 407 - 422
  • [42] Cystic fibrosis: gene therapy or preventive gene transfer?
    L Drittanti
    MV Masciovecchio
    J Gabbarini
    M Vega
    Gene Therapy, 1997, 4 : 1001 - 1003
  • [43] Cystic fibrosis: gene therapy or preventive gene transfer?
    Drittanti, L
    Masciovecchio, MV
    Gabbarini, J
    Vega, M
    GENE THERAPY, 1997, 4 (10) : 1001 - 1003
  • [44] Moving forward with cystic fibrosis gene therapy
    Griesenbach, U.
    HUMAN GENE THERAPY, 2011, 22 (10) : A6 - A6
  • [45] Moving forward: cystic fibrosis gene therapy
    Griesenbach, Uta
    Alton, Eric W. F. W.
    HUMAN MOLECULAR GENETICS, 2013, 22 : R52 - R58
  • [46] GENE-THERAPY FOR CYSTIC-FIBROSIS
    DODGE, JA
    NATURE MEDICINE, 1995, 1 (03) : 182 - 182
  • [47] Liposome mediated gene therapy for cystic fibrosis
    Geddes, DM
    GENE DELIVERY SYSTEMS: A STATE-OF-THE-ART REVIEW, 1996, : 223 - 227
  • [48] Gene therapy for cystic fibrosis by means of aerosol
    Rochat, T
    Morris, MA
    JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2002, 15 (02): : 229 - 235
  • [49] Gene therapy progress and prospects: cystic fibrosis
    Griesenbach, U.
    Geddes, D. M.
    Alton, E. W. F. W.
    GENE THERAPY, 2006, 13 (14) : 1061 - 1067
  • [50] GENE-THERAPY FOR CYSTIC-FIBROSIS
    ALTON, EWFW
    JOURNAL OF INHERITED METABOLIC DISEASE, 1995, 18 (04) : 501 - 507